Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Martin Loveček

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9775-9643; OpenAlex author ID A5043871340. Sources: OpenAlex.

Their work

Papers
41 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
84
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 4 papers · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: 1 paper · 2021: 6 papers · 2022: 2 papers · 2023: 6 papers · 2024: 3 papers · 2025: 4 papers · 2026: 4 papers

Papers 41

  1. Benzoyl chloride derivatization improves selectivity and sensitivity of lipidomic quantitation in human serum of pancreatic cancer patients using RP-UHPLC/MS/M… Co-author DOI 10.1007/s00216-025-06151-0↗
  2. RP-UHPLC/MS/MS provides enhanced lipidomic profiling of human serum in pancreatic cancer. Co-author DOI 10.1016/j.aca.2025.344952↗
  3. Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum. Co-author DOI 10.1038/s43856-026-01445-5↗
  4. Claims-based reconstruction of the pancreatic cancer care pathway links centralization of care to survival Co-author DOI 10.64898/2026.10.17.26365423↗
  5. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  6. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions. Co-author DOI 10.1002/ueg2.70118↗
  7. Potential for Clinical Management of Pancreatic Cancer Through Whole Exome Profiling of Site-Specific Metastases and Matched Primary Tumors. Co-author DOI 10.1016/j.labinv.2025.104205↗
  8. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  9. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  10. Oligometastatic pancreatic cancer - prognostic factors for oncosurgical individualized therapy. Last author DOI 10.48095/ccrvch2024421↗
  11. Complete pathological response after neoadjuvant chemotherapy and the benefit of subsequent surgery in oligometastatic pancreatic cancer patient. First author DOI 10.48095/ccrvch2024454↗
  12. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  13. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  14. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  15. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  16. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  17. Morphine Analgesia, Cannabinoid Receptor 2, and Opioid Growth Factor Receptor Cancer Tissue Expression Improve Survival after Pancreatic Cancer Surgery. Co-author DOI 10.3390/cancers15164038↗
  18. Pancreatic cancer in chronic pancreatitis – the diagnostic and therapeutic dilemma; an overview of cases Co-author DOI 10.33699/pis.2022.101.11.549-556↗
  19. Isolated Gastric Metastases of Pancreatic Ductal Adenocarcinoma following Radical Resection-Impact of Endosonography-Guided Fine Needle Aspiration Tract Seedin… Co-author DOI 10.3390/biomedicines10061392↗
  20. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  21. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  22. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  23. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  24. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  25. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  26. Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection. Co-author DOI 10.3390/jcm9082440↗
  27. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  28. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgz006↗
  29. Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alteration… Co-author DOI 10.2147/cmar.s185352↗
  30. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. Co-author DOI 10.2217/pgs-2018-0073↗
  31. Tumor grade as significant prognostic factor in pancreatic cancer: validation of a novel TNMG staging system. Last author DOI 10.4149/neo_2018_171012n650↗
  32. [The effect of circulating tumor cells on the survival of patients with pancreatic cancer 5-year results]. Last author DOI 10.33699/pis.2018.97.2.94-98↗
  33. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of th… Co-author DOI 10.3748/wjg.v23.i35.6420↗
  34. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Co-author DOI 10.3892/ol.2017.6946↗
  35. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  36. Long-term survival after resections for pancreatic ductal adenocarcinoma. Single centre study. Co-author DOI 10.5507/bp.2016.011↗
  37. [Current status regarding surgical treatment of pancreatic cancer in the Czech Republic]. Co-author PMID 27226268↗
  38. [The survival of patients with radically non-resectable pancreatic cancer]. Last author PMID 27410755↗
  39. [Determination of CEA, EGFR and hTERT expression in peritoneal lavage in patients with pancreatic adenocarcinoma using RT - PCR method]. Last author PMID 26766154↗
  40. [Surgical therapy of pancreatic cancer - 5 years survival]. Co-author PMID 26766155↗
  41. Occult tumour cells in peritoneal lavage are a negative prognostic factor in pancreatic cancer. Co-author DOI 10.5507/bp.2012.061↗

Closest collaborators

The 25 strongest of 84 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Beatrice Mohelníková-Duchoňová · 10 shared papers, 2017–2026 · strength 1.62
  2. Bohuslav Melichar · 7 shared papers, 2017–2026 · strength 1.14
  3. Ondřej Peterka · 3 shared papers, 2026 · strength 0.83
  4. Michal Holčapek · 3 shared papers, 2026 · strength 0.83
  5. Aleš Langer · 3 shared papers, 2024–2025 · strength 0.72
  6. Pavel Souček · 6 shared papers, 2017–2025 · strength 0.65
  7. Dušan Klos · 8 shared papers, 2013–2022 · strength 0.63
  8. Zuzana Lásko · 2 shared papers, 2026 · strength 0.59
  9. Beatrice Mohelníková Duchoňová · 2 shared papers, 2024 · strength 0.50
  10. R Havlík · 9 shared papers, 2013–2019 · strength 0.48
  11. Zdeněk Kala · 4 shared papers, 2017–2023 · strength 0.40
  12. Č Neoral · 7 shared papers, 2013–2019 · strength 0.36
  13. Viktor Hlaváč · 3 shared papers, 2017–2025 · strength 0.35
  14. Gleb Donin · 1 shared paper, 2026 · strength 0.33
  15. Daniel Laubr · 1 shared paper, 2026 · strength 0.33
  16. Marián Hajdúch · 4 shared papers, 2013–2023 · strength 0.33
  17. Jan Hlavsa · 4 shared papers, 2016–2020 · strength 0.28
  18. Linda Bebarova · 4 shared papers, 2015–2018 · strength 0.25
  19. Ingrid Garajová · 1 shared paper, 2025 · strength 0.25
  20. Giulia Gasparini · 1 shared paper, 2025 · strength 0.25
  21. Carmen Mota Reyes · 1 shared paper, 2025 · strength 0.25
  22. Elisa Giovannetti · 1 shared paper, 2025 · strength 0.25
  23. İhsan Ekin Demir · 1 shared paper, 2025 · strength 0.25
  24. Pinar Uysal Onganer · 1 shared paper, 2025 · strength 0.25
  25. Stefano Crippa · 1 shared paper, 2025 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.